Cancer mutations can no longer respond to normal cellular signals
Deep within the machinery of the cell, a protein called SPOP has long kept a secret that cancer researchers could not fully read. Scientists at St. Jude Children's Research Hospital have now revealed that SPOP moves between two distinct physical forms—a resting 'double-donut' and an active filament—and that cancer mutations work by locking the protein into one state, severing its ability to respond to the cell's own instructions. The discovery transforms a collection of previously mysterious tumor mutations into legible failures of molecular regulation, and opens a path toward therapies that might one day restore the balance cancer has broken.
- A protein central to cancer biology has been hiding a structural secret: it shapeshifts between a massive ring-like resting form and a thread-like active form, and cancer exploits this switch.
- Mutations that were scattered across SPOP's structure and long defied explanation can now be understood as locks that freeze the protein in one position, deaf to the cell's regulatory signals.
- The stakes are high because SPOP normally keeps three powerful gene regulators—BRD2, BRD3, and BRD4—in check, and losing that control is a known driver of cancer development.
- Cryo-electron microscopy, deployed across hundreds of hours at St. Jude's facilities, was required to capture both structural states and map where each form lives inside the cell nucleus.
- The inactive double-donut form anchors itself in nuclear speckles, while gain-of-function mutations push SPOP out of those compartments entirely, suggesting location and state are tightly linked.
- Researchers now have a structural framework for designing therapies that could manipulate SPOP's on-off transition, though many cancer mutations in this protein still await explanation.
Scientists at St. Jude Children's Research Hospital have answered a question that has quietly frustrated cancer researchers for years: why do certain mutations in the protein SPOP appear in tumors when no one could explain what harm they caused?
SPOP is a gatekeeper. It sits at the heart of a cellular machine responsible for keeping the levels of other proteins in check—among them BRD2, BRD3, and BRD4, three gene regulators whose overabundance can tip a cell toward cancer. Some SPOP mutations were already understood to weaken its grip on these targets. But many others, spread across the protein's structure, remained mysterious. Tanja Mittag and her team set out to close that gap.
Using cryo-electron microscopy, the researchers captured SPOP in two entirely different physical forms. In its resting state, dozens of SPOP molecules stack into a structure resembling two donuts placed on top of each other—a formation large enough to encircle an entire ribosome. When activated by its partner protein Cullin-3, SPOP abandons that shape and stretches into a long filament. This transition is the protein's on-off switch.
Cancer mutations, the team found, break this switch in one of two directions. Gain-of-function mutations lock SPOP in its active filament form; loss-of-function mutations trap it in the double-donut. Either way, the protein can no longer respond to the cellular signals that should govern when it works and when it rests. As researcher Matt Cuneo put it, the mutations allow SPOP to bypass normal regulation entirely.
The location of these states inside the cell also proved meaningful. The inactive double-donut form concentrates in nuclear speckles—specialized compartments within the nucleus—while gain-of-function mutations push SPOP away from them, suggesting that the speckle is where the protein waits before being called to action.
The findings reframe a collection of previously inexplicable mutations as comprehensible failures of molecular balance, and they point toward a new therapeutic direction: if the pathways governing SPOP's transition between states can be understood, they might be manipulated to fight cancer. Much work remains, and many SPOP mutations are still unexplained, but the structural foundation is now in place.
Scientists at St. Jude Children's Research Hospital have solved a puzzle that has long troubled cancer researchers: how certain mutations in a protein called SPOP contribute to disease. The answer lies in understanding a delicate molecular dance—one that cancer mutations brutally interrupt.
SPOP is a gatekeeper protein. It sits at the center of a cellular machine called the E3 ubiquitin ligase complex, whose job is to regulate the levels of other proteins inside cells. When SPOP works properly, it keeps three particularly important proteins—BRD2, BRD3, and BRD4—in balance. These three are gene regulators, and when their levels get out of control, cancer can develop. Many SPOP mutations found in tumors make it harder for SPOP to grab onto these target proteins, which explains why those mutations are dangerous. But other SPOP mutations, scattered throughout the protein's structure, have remained mysterious. Researchers knew they appeared in cancer, but couldn't explain why. That gap in understanding is what Tanja Mittag and her team at St. Jude set out to close.
Using cryo-electron microscopy—a technique that can reveal the three-dimensional architecture of molecules—the researchers captured SPOP in two distinct states. When inactive, individual SPOP molecules stack together into a structure that looks like two donuts piled on top of each other. This double-donut formation is enormous, made of between 22 and 30 SPOP molecules arranged in rings so large they could encircle an entire ribosome. When the protein is activated by a binding partner called Cullin-3, it transforms into something entirely different: a long, thread-like filament. This shift from donut to filament is the on-off switch that controls whether SPOP is working or resting.
The discovery reframes how scientists understand cancer mutations in SPOP. Gain-of-function mutations—the ones that make SPOP overactive—lock the protein into its filament state. Loss-of-function mutations, which weaken SPOP, trap it in the double-donut configuration. Either way, the mutations break the normal balance. Cancer cells with these mutations have SPOP stuck in one position, unable to respond to the cellular signals that should tell it when to turn on and off. The protein can no longer hear the instructions that keep it regulated.
The location where SPOP operates also matters. Inside the cell nucleus, SPOP concentrates in structures called nuclear speckles—membraneless compartments where certain cellular work happens. The researchers found that the inactive double-donut form strongly associates with these speckles, while gain-of-function mutations push SPOP away from them. This suggests that the speckle is where SPOP rests, and activation causes it to leave and go to work elsewhere in the nucleus.
Matt Cuneo, one of the researchers who led the structural work, emphasized the significance of identifying the double-donut as an autoinhibited, off state. "The cancer mutations can bypass this regulation," he explained. "They are no longer responding to normal cellular signals that switch SPOP between the inactive double-donut structure and the active filament." This finding transforms previously unexplained mutations from mysteries into comprehensible failures of regulation.
The work opens a new therapeutic avenue. If researchers can understand the cellular pathways that govern the transition between SPOP's two states, they might be able to manipulate those pathways to fight cancer. Mohamed-Raafet Ammar, another co-first author, noted that the newly identified double-donut structure provides a framework for thinking about how to target SPOP in tumors. The challenge ahead is substantial—the team used hundreds of hours of access to St. Jude's cryo-electron microscopy equipment to reach these conclusions, and they acknowledge that many cancer-associated SPOP mutations remain unexplained. But the foundation is now in place. The next phase will involve understanding the full cellular context in which SPOP's balance between rest and activity unfolds, and whether that understanding can be translated into drugs that restore the protein's normal regulation in cancer cells.
Citas Notables
SPOP is unique among ubiquitin ligases in that it assembles into long filaments—no other substrate receptor we know of does this—but we didn't understand what this brings to the table.— Tanja Mittag, Department of Structural Biology, St. Jude
The cancer mutations can bypass this regulation, meaning they are no longer responding to normal cellular signals that switch SPOP between the inactive double-donut structure and the active filament.— Matt Cuneo, Department of Structural Biology, St. Jude
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that SPOP switches between two physical shapes? Isn't a protein just a protein?
Because the shape determines whether it's working or sleeping. The double-donut is the off position—it's SPOP telling itself to stop. The filament is the on position. Cancer mutations lock it into one shape, so the cell can't turn it on and off anymore. It's like a light switch that gets jammed.
And the mutations that were previously unexplained—what makes them suddenly explainable now?
Before, researchers could only explain mutations that directly broke SPOP's ability to grab its target proteins. But these other mutations were in different parts of the protein, and nobody understood what they did. Now we know they disrupt the balance between the two states. They're not breaking the grip—they're breaking the switch.
The double-donut is made of 22 to 30 individual SPOP molecules. Why does it need to be so large?
It's an elegant design. SPOP has to assemble into long filaments first before it can circle back and form the donut. The size allows it to do both—to be active when needed, and to collapse into this massive, stable inactive form when it needs to rest. It's a way of storing the protein in a locked state.
You mentioned nuclear speckles. What happens if a cancer mutation pushes SPOP out of those compartments?
The speckles appear to be where SPOP goes to be inactive, to be held in check. If a mutation drives it away, SPOP stays active in the surrounding nucleus. It's constantly working, constantly degrading its target proteins, throwing the cell's balance out of control.
Can this knowledge actually lead to a drug?
That's the hope. If you understand the pathways that control the switch between the two states, you could theoretically intervene—either to force an overactive SPOP back into its inactive form, or to activate a weakened one. But the researchers are honest: they've solved one piece of the puzzle, not the whole thing. Many mutations still don't fit the model.